Rohtak News Magazine

Spinal Muscular Atrophy Market is Projected to Boost at a Moderate Growth Rate by 2032 – DelveInsight | Key Companies – Genentech, Biogen, Novartis Pharmaceuticals

 Breaking News
  • No posts were found

Spinal Muscular Atrophy Market is Projected to Boost at a Moderate Growth Rate by 2032 – DelveInsight | Key Companies – Genentech, Biogen, Novartis Pharmaceuticals

August 23
00:17 2022
Spinal Muscular Atrophy Market is Projected to Boost at a Moderate Growth Rate by 2032 - DelveInsight | Key Companies - Genentech, Biogen, Novartis Pharmaceuticals
DelveInsight’s “Spinal Muscular Atrophy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of Spinal Muscular Atrophy, historical and forecasted epidemiology as well as the Spinal Muscular Atrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Spinal Muscular Atrophy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage pipeline products will significantly revolutionize the Spinal Muscular Atrophy market dynamics. 

 

DelveInsight’s “Spinal Muscular Atrophy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of Spinal Muscular Atrophy, historical and forecasted epidemiology as well as the Spinal Muscular Atrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some of the key facts of the Spinal Muscular Atrophy Market Report:

  • The Spinal Muscular Atrophy market size is anticipated to grow with a significant CAGR during the study period (2019-2032) 
  • As per secondary analysis, it can be concluded that Spinal Muscular Atrophy Type 1 occurs equally in men and women 
  • According to the National Organization for Rare Disorders (NORD), the prevalence of all types of SMA has been estimated to be 4-7.8 per 100,000 live births 
  • Infants with SMA type 1 usually appear normal at birth but experience severe weakness before 6 months of age 
  • Key Spinal Muscular Atrophy Companies: Genentech, Biogen, Novartis Pharmaceuticals, and others
  • Key Spinal Muscular Atrophy Therapies: Reldesemtiv, Branaplam, Nusinersen, RO7204239, Risdiplam, and others
  • Spinal Muscular Atrophy type 1, also known as infantile Spinal Muscular Atrophy (SMA) or Werdnig-Hoffmann disease, is the most common type of Spinal Muscular Atrophy (SMA), affecting approximately 60% of infants born with Spinal Muscular Atrophy (SMA) and is also a severe form of the disease

 

Request a sample for the Spinal Muscular Atrophy Market Report

 

Key benefits of the Spinal Muscular Atrophy Market report:

  1. The spinal Muscular Atrophy market report covers a descriptive overview and comprehensive insight of the Epidemiology and Spinal Muscular Atrophy market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Spinal Muscular Atrophy market report provides insights into current and emerging therapies.
  3. Spinal Muscular Atrophy market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Spinal Muscular Atrophy market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Spinal Muscular Atrophy market.

 

Discover more about therapies set to grab major Spinal Muscular Atrophy market share @ Spinal Muscular Atrophy market forecast

 

Spinal Muscular Atrophy Overview

Spinal Muscular Atrophy is an autosomal recessive rare neuromuscular disorder that is characterized by progressive muscle wasting because of the loss of motor neurons in the spinal cord (anterior horn), which controls voluntary muscle movement. SMA is one of the most common causes of infant death and mobility impairment. It mostly affects proximal muscles and respiratory muscles. The most common form of SMA is known as ‘5q SMA’ due to its genetic cause. 

SMA follows the autosomal mode of inheritance and its onset ranges from infants to adolescence. Human chromosome5q has two identical genes SMN1 and SMN2. SMN1 encodes 100% fully functional SMN protein, whereas SMN2 encodes only 10-20% of functional SMN protein. Mutation of SMN1 is the main reason for this disorder and the severity of the disease depends on the number of SMN2 gene copies. A healthy person carries 2 copies of the SMN2 gene, but in SMA-affected patients, it can vary from 1 to 4. Greater the number of SMN2 gene copies, the milder the effect of the disorder. The other SMAs form a genetically very heterogeneous group of rare disorders, differing in their mode of inheritance, the topography of the muscular deficit, and the association with other neurological abnormalities. 

 

Spinal Muscular Atrophy Symptoms 

When SMA symptoms are present at birth or by the age of 6 months, the disease is called SMA type 1. The symptoms observed in babies are – muscle weakness, a weak cry, and breathing distress. 

The Spinal Muscular Atrophy symptoms include –

  • Muscle Weakness
  • Limited Joint Mobility
  • Breathing problems
  • Scoliosis
  • Delayed gross motor skills

 

Spinal Muscular Atrophy Epidemiology Segmentation:

The Spinal Muscular Atrophy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Spinal Muscular Atrophy
  • Prevalent Cases of Spinal Muscular Atrophy by severity
  • Gender-specific Prevalence of Spinal Muscular Atrophy
  • Diagnosed Cases of Episodic and Chronic Spinal Muscular Atrophy

 

Spinal Muscular Atrophy Market 

The dynamics of the Spinal Muscular Atrophy market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Nusinersen, RO7204239, and others during the forecasted period 2019-2032.

 

Download the report to understand which factors are driving Spinal Muscular Atrophy epidemiology trends @ Spinal Muscular Atrophy Epidemiological Insights

 

Spinal Muscular Atrophy Therapies

  • Reldesemtiv 
  • Branaplam
  • Nusinersen
  • RO7204239
  • Risdiplam 

 

Spinal Muscular Atrophy Key Companies 

  • Genentech
  • Biogen
  • Novartis Pharmaceuticals

 

Scope of the Spinal Muscular Atrophy Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Spinal Muscular Atrophy Companies: Genentech, Biogen, Novartis Pharmaceuticals, and others
  • Key Spinal Muscular Atrophy Therapies: Reldesemtiv , Branaplam, Nusinersen, RO7204239, Risdiplam , and others
  • Therapeutic Assessment: Spinal Muscular Atrophy current marketed and Spinal Muscular Atrophy emerging therapies
  • Migraine Market Dynamics:  Spinal Muscular Atrophy market drivers and barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, Spinal Muscular Atrophy  Market Access and Reimbursement

 

Spinal Muscular Atrophy Market Drivers

  • Newborn Screening for SMA
  • Promising Upcoming Launches and Approval 
  • Raising Awareness for SMA

 

Spinal Muscular Atrophy Market Barriers

  • High-treatment Cost
  • Competition for Emerging Therapies

 

Table of Contents

1. Spinal Muscular Atrophy Market Report Introduction

2. Executive Summary for Spinal Muscular Atrophy

3. SWOT analysis of Spinal Muscular Atrophy

4. Spinal Muscular Atrophy Patient Share (%) Overview at a Glance

5. Spinal Muscular Atrophy Market Overview at a Glance

6. Spinal Muscular Atrophy Disease Background and Overview

7. Spinal Muscular Atrophy Epidemiology and Patient Population

8. Country-Specific Patient Population of Spinal Muscular Atrophy 

9. Spinal Muscular Atrophy Current Treatment and Medical Practices

10. Spinal Muscular Atrophy Unmet Needs

11. Spinal Muscular Atrophy Emerging Therapies

12. Spinal Muscular Atrophy Market Outlook

13. Country-Wise Spinal Muscular Atrophy Market Analysis (2019–2032)

14. Spinal Muscular Atrophy Market Access and Reimbursement of Therapies

15. Spinal Muscular Atrophy Market drivers

16. Spinal Muscular Atrophy Market barriers

17.  Spinal Muscular Atrophy Appendix

18. Spinal Muscular Atrophy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Spinal Muscular Atrophy treatment, visit @ Spinal Muscular Atrophy Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles